Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

HeartMate II left ventricular assist device also improves right side heart function

A state-of-the-art heart pump, designed to maintain a continuous flow of blood in end-stage cardiac patients with damage to the left side of the heart, also improves function on the right side of the heart, according to researchers at Henry Ford Hospital's Heart and Vascular Institute.

27 May 2010

Pfizer plans recruitment halt to EMPHASIS-HF trial

Pfizer Inc. announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial's independent Executive Steering Committee (ESC). The recommendations follow a second interim analysis by the independent Data Safety Monitoring Committee (DSMC) of the EMPHASIS-HF trial confirming the study has reached its primary efficacy endpoint early according to the protocol pre-defined stopping rules.

27 May 2010

New clinical data for CoreValve transcatheter aortic valve replacement system presented at EuroPCR

New clinical data presented today at EuroPCR demonstrate positive long-term performance and durability for the CoreValve transcatheter aortic valve replacement system from Medtronic, Inc. Two-year results from the pivotal 18-French CoreValve multicenter prospective study provide important additional evidence supporting wider use of the world's market-leading transcatheter aortic valve.

26 May 2010

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

POZEN Inc., announced today the receipt of a $20 million milestone payment from AstraZeneca for the U.S. Food and Drug Administration approval of VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets on April 30th. POZEN will transfer ownership of the Investigational New Drug application and New Drug Application for VIMOVO to AstraZeneca over the next few weeks.

26 May 2010

SunTech Medical's clinical-grade blood pressure technology selected for new Portable PFS

SunTech Medical, a leading manufacturer of blood pressure monitors and OEM non-invasive blood pressure modules, is pleased to announce the selection of their clinical-grade blood pressure technology for the new Portable Pulmonary Function System by Damec.

26 May 2010

EIRMC, West Valley Medical Center to continue to serve Humana's Medicare Advantage members

Eastern Idaho Regional Medical Center (EIRMC), a full-service regional medical center in Idaho Falls, and West Valley Medical Center, a community hospital in Caldwell, will continue to provide in-network medical care to all Medicare Advantage members enrolled in plans offered by Humana, under terms of a renewal agreement announced today.

26 May 2010

t2c001 product obtains certificate under EMA regulations for ATMPs

t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the quality of its lead product t2c001 has been certified by the European Medicines Agency.

25 May 2010

Researchers explore impact of asymptomatic LV dysfunction in vascular surgery patients

Symptomatic heart failure prior to surgery is routinely acknowledged as a risk factor for adverse outcomes for both cardiac and non-cardiac surgeries. In a new study published in the June Anesthesiology, researchers delve further into the implications of cardiac problems on postoperative outcomes, exploring preoperative diagnosis and impact of asymptomatic left ventricular dysfunction in vascular surgery patients.

25 May 2010

NormOxys raises $17.5M in Series B financing round

NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has raised $17.5 million in a Series B financing round. The financing was led by a new investor, Care Capital, LLC, with participation from existing venture investor Index Ventures.

24 May 2010

Phase 1 clinical trial of OXY111A initiated

NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has initiated a Phase 1 clinical trial of OXY111A, a novel allosteric modulator of affinity of oxygen to hemoglobin. NormOxys plans to initially develop this compound as a treatment for chronic heart failure and cancer indications.

24 May 2010

European researchers define research priorities in biogerontology

The quality of the medical care for geriatric patients is a major investment for society and must imperatively be a research priority in Europe. This is why 50 European researchers, met on May 17 - 19 in Brussels, to define the research priorities in the field of biogerontology for the next 10 to 15 years.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.

21 May 2010

Initial results of MUSIC Trial using PD2i in chronic heart failure patients released

David H. Fater, CEO of Vicor Technologies, Inc., today announced the initial results of a study designed to analyze data from the Merte Subita en Insufficiencia Cardiaca Trial using its PD2i- algorithm and software. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i- nonlinear algorithm and software.

20 May 2010

ABBOTT PRISM Chagas test receives FDA approval

Abbott received Biologic License Application (BLA) approval from the United States Food and Drug Administration (FDA) for the ABBOTT PRISM Chagas test. The test is a fully automated blood screening assay that can detect antibodies to Trypansoma cruzi (T. cruzi), a parasite found only in the Americas and most commonly acquired through contact with the blood-sucking triatomine or "kissing bug."

19 May 2010

Abiomed's Impella revenue for full fiscal year 2010 up 59% to $57.8 million

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today reported fourth quarter fiscal 2010 revenue of $23.0 million, up 17% compared to revenue of $19.6 million for the same period of fiscal 2009.

19 May 2010

Positive data from Geron's TAT153 small molecule telomerase activator in animal model of IPF

Geron Corporation today announced positive data on its orally available small molecule telomerase activator, TAT153, in an animal model of idiopathic pulmonary fibrosis (IPF). The data show that administration of TAT153 increased telomerase activity in the lung tissue, reduced inflammation, preserved functional lung tissue, slowed disease progression and attenuated loss of pulmonary function.

19 May 2010

eMedonline telemonitoring system developed to help patients transition from inpatient to outpatient setting

A clinical study is underway at Nyack Hospital to evaluate the use of cellphone-based technology to monitor medication adherence in discharged heart failure patients. The study is using the eMedonline telemonitoring system developed by Leap of Faith Technologies to help patients transition from the inpatient to outpatient setting.

19 May 2010

Market for telehealth and home health monitoring to grow up to $7.7 billion by 2012: Survey

AMERICAN TELEMEDICINE ASSOCIATION ANNUAL MEETING - Health care delivery in the United States will undergo dramatic changes over the next 10 years through the adoption of telehealth, according to a national survey of health care and information technology professionals sponsored by Intel Corporation.

19 May 2010

REVEAL risk score calculator provides innovative approach to better understand PAH

Actelion Ltd announced today that findings from the REVEAL Registry have confirmed the clinical utility of the REVEAL risk score calculator, a new tool designed to predict 1-year survival in patients with pulmonary arterial hypertension according to data presented at the American Thoracic Society's Annual International Conference.

18 May 2010

Heart Failure News and Research

Further Reading

HeartMate II left ventricular assist device also improves right side heart function

Pfizer plans recruitment halt to EMPHASIS-HF trial

New clinical data for CoreValve transcatheter aortic valve replacement system presented at EuroPCR

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

SunTech Medical's clinical-grade blood pressure technology selected for new Portable PFS

EIRMC, West Valley Medical Center to continue to serve Humana's Medicare Advantage members

t2c001 product obtains certificate under EMA regulations for ATMPs

Researchers explore impact of asymptomatic LV dysfunction in vascular surgery patients

NormOxys raises $17.5M in Series B financing round

Phase 1 clinical trial of OXY111A initiated

European researchers define research priorities in biogerontology

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Genentech to present new data for targeted cancer medicines at 46th ASCO

Initial results of MUSIC Trial using PD2i in chronic heart failure patients released

ABBOTT PRISM Chagas test receives FDA approval

Abiomed's Impella revenue for full fiscal year 2010 up 59% to $57.8 million

Positive data from Geron's TAT153 small molecule telomerase activator in animal model of IPF

eMedonline telemonitoring system developed to help patients transition from inpatient to outpatient setting

Market for telehealth and home health monitoring to grow up to $7.7 billion by 2012: Survey

REVEAL risk score calculator provides innovative approach to better understand PAH

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News